CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade ReShape Lifesciences Inc. - RSLS CFD

0.38
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* 0.42
1-Year Change* 10.53%
Day's Range* 0.38 - 0.55
52 wk Range 0.15-2.22
Average Volume (10 days) 204.12K
Average Volume (3 months) 3.86M
Market Cap 4.21M
P/E Ratio -100.00K
Shares Outstanding 24.18M
Revenue 12.18M
EPS -4.40
Dividend (Yield %) N/A
Beta -0.18
Next Earnings Date Mar 27, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 13, 2023 0.38 -0.02 -5.00% 0.40 0.55 0.38
Oct 12, 2023 0.40 -0.01 -2.44% 0.41 0.49 0.38
Sep 29, 2023 0.40 -0.05 -11.11% 0.45 0.49 0.38
Sep 28, 2023 0.41 -0.11 -21.15% 0.52 0.55 0.41
Sep 27, 2023 0.50 -0.01 -1.96% 0.51 0.51 0.50
Sep 26, 2023 0.57 -0.01 -1.72% 0.58 0.60 0.57
Sep 25, 2023 0.59 0.02 3.51% 0.57 0.59 0.55
Sep 22, 2023 0.57 -0.04 -6.56% 0.61 0.62 0.57
Sep 21, 2023 0.58 -0.06 -9.38% 0.64 0.64 0.57
Sep 20, 2023 0.64 0.03 4.92% 0.61 0.65 0.61
Sep 19, 2023 0.63 -0.05 -7.35% 0.68 0.68 0.62
Sep 18, 2023 0.67 -0.06 -8.22% 0.73 0.73 0.65
Sep 15, 2023 0.70 0.00 0.00% 0.70 0.70 0.68
Sep 14, 2023 0.74 -0.05 -6.33% 0.79 0.79 0.72
Sep 13, 2023 0.73 0.00 0.00% 0.73 0.75 0.73
Sep 12, 2023 0.78 -0.07 -8.24% 0.85 0.85 0.76
Sep 11, 2023 0.85 -0.02 -2.30% 0.87 0.87 0.82
Sep 8, 2023 0.81 -0.05 -5.81% 0.86 0.86 0.79
Sep 7, 2023 0.84 -0.05 -5.62% 0.89 0.90 0.84
Sep 6, 2023 0.91 0.03 3.41% 0.88 1.25 0.88

ReShape Lifesciences Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 13.6 1.588 3.281 9.101 9.914
Revenue 13.6 1.588 3.281 9.101 9.914
Cost of Revenue, Total 5.252 1.004 2.95 5.423 4.829
Gross Profit 8.348 0.584 0.331 3.678 5.085
Total Operating Expense 72.162 13.54 26.511 46.066 44.305
Selling/General/Admin. Expenses, Total 31.275 8.776 16.668 29.946 28.829
Research & Development 2.522 2.45 6.893 10.697 10.647
Operating Income -58.562 -11.952 -23.23 -36.965 -34.391
Interest Income (Expense), Net Non-Operating -0.664 0.029 -0.385 -0.226 -0.135
Other, Net -2.813 -0.411 -0.061 -0.189 -0.239
Net Income Before Taxes -62.039 -12.334 -23.676 -37.38 -34.765
Net Income After Taxes -61.933 -12.334 -23.676 -37.38 -34.765
Net Income Before Extra. Items -61.933 -12.334 -23.676 -37.38 -34.765
Net Income -61.933 -12.334 -23.676 -37.38 -34.765
Income Available to Common Excl. Extra. Items -61.933 -12.334 -23.676 -37.38 -34.765
Income Available to Common Incl. Extra. Items -61.933 -12.334 -23.676 -37.38 -34.765
Diluted Net Income -61.933 -12.334 -23.676 -37.38 -34.765
Diluted Weighted Average Shares 12.3785 2.57943 1.56891 0.63455 0.55723
Diluted EPS Excluding Extraordinary Items -5.00327 -4.78168 -15.0907 -58.9079 -62.3888
Diluted Normalized EPS -3.26449 -4.27382 -15.0907 -58.9079 -62.3888
Total Extraordinary Items 0
Dividends per Share - Common Stock Primary Issue 0
Unusual Expense (Income) 33.113 1.31
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 2.44 3.142 3.708 3.529 3.221
Revenue 2.44 3.142 3.708 3.529 3.221
Cost of Revenue, Total 1.222 1.366 1.573 1.376 0.937
Gross Profit 1.218 1.776 2.135 2.153 2.284
Total Operating Expense 10.84 38.699 18.692 7.332 7.438
Selling/General/Admin. Expenses, Total 8.87 8.304 15.548 5.752 3.97
Research & Development 0.748 0.277 1.571 0.103 0.571
Unusual Expense (Income) 0 28.752 0 0.101 1.96
Operating Income -8.4 -35.557 -14.984 -3.803 -4.217
Interest Income (Expense), Net Non-Operating 0.015 -0.03 0.068 -0.071 -0.632
Other, Net 0.013 0 -2.813 0
Net Income Before Taxes -8.372 -35.587 -17.729 -3.874 -4.849
Net Income After Taxes -8.215 -35.458 -17.699 -3.902 -4.874
Net Income Before Extra. Items -8.215 -35.458 -17.699 -3.902 -4.874
Net Income -8.215 -35.458 -17.699 -3.902 -4.874
Income Available to Common Excl. Extra. Items -8.215 -35.458 -17.699 -3.902 -4.874
Income Available to Common Incl. Extra. Items -8.215 -35.458 -17.699 -3.902 -4.874
Diluted Net Income -8.215 -35.458 -17.699 -3.902 -4.874
Diluted Weighted Average Shares 18.5396 17.874 11.9974 8.22614 3.92799
Diluted EPS Excluding Extraordinary Items -0.44311 -1.98378 -1.47524 -0.47434 -1.24084
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.44311 -0.93819 -1.47524 -0.46636 -0.9165
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 30.255 7.835 18.235 28.647 51.755
Cash and Short Term Investments 22.765 3.905 14.055 23.735 44.4
Cash & Equivalents 22.765 3.905 14.055 21.187 21.108
Short Term Investments 0 2.548 23.292
Total Receivables, Net 2.815 3.15 0.285 0.882 4.308
Accounts Receivable - Trade, Net 2.815 0 0.285 0.87 4.223
Total Inventory 3.003 0 1.936 1.58 1.418
Prepaid Expenses 0.736 0.599 1.89 2.329 1.514
Other Current Assets, Total 0.936 0.181 0.069 0.121 0.115
Total Assets 54.258 10.617 20.393 30.386 53.101
Property/Plant/Equipment, Total - Net 1.72 1.478 2.158 1.739 1.346
Property/Plant/Equipment, Total - Gross 2.06 4.082 4.484 3.718 2.761
Accumulated Depreciation, Total -0.34 -2.604 -2.326 -1.979 -1.415
Total Current Liabilities 7.331 5.046 3.977 17.231 10.011
Payable/Accrued 3.468
Accrued Expenses 2.407 4.431 2.881 5.79 6.267
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0.024 9.93 1.958
Other Current Liabilities, Total 1.456 0 0.424 0.352 0.51
Total Liabilities 8.186 5.952 4.544 17.279 17.988
Total Long Term Debt 0 0.43 0 0 7.964
Long Term Debt 0 0.43 0 7.964
Total Equity 46.072 4.665 15.849 13.107 35.113
Preferred Stock - Non Redeemable, Net 0
Common Stock 0.018 0.008 0.008 0.023 0.018
Additional Paid-In Capital 622.906 189.421 188.271 161.838 146.474
Retained Earnings (Accumulated Deficit) -576.76 -184.764 -172.43 -148.754 -111.374
Other Equity, Total -0.092 0 -0.005
Total Liabilities & Shareholders’ Equity 54.258 10.617 20.393 30.386 53.101
Total Common Shares Outstanding 17.8319 2.59021 2.57467 0.78377 0.58335
Accounts Payable 0.615 0.648 1.159 1.276
Other Liabilities, Total 0.3 0.476 0.567 0.048 0.013
Other Long Term Assets, Total 1.456 1.304
Intangibles, Net 20.827
Deferred Income Tax 0.555
Total Preferred Shares Outstanding 0.09539
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 23.627 30.255 37.589 65.605 12.794
Cash and Short Term Investments 15.41 22.765 29.243 40.163 8.972
Cash & Equivalents 15.41 22.765 29.243 40.163 8.972
Total Receivables, Net 2.41 2.815 3.457 3.422 3.15
Prepaid Expenses 0.597 0.736 0.693 1.114 0.495
Other Current Assets, Total 1.212 0.936 0.99 18.012 0.177
Total Assets 47.27 54.258 90.698 120 17.343
Property/Plant/Equipment, Total - Net 1.895 1.72 2.052 2.22 1.312
Property/Plant/Equipment, Total - Gross 0.524 2.06 0.45 0.632 3.982
Accumulated Depreciation, Total -0.34 -2.67
Other Long Term Assets, Total 1.377 1.456 1.535 1.628 3.237
Total Current Liabilities 8.151 7.331 10.336 60.496 6.863
Accounts Payable 3.095 0.582
Accrued Expenses 2.695 2.899 3.128 53.479 5.851
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 2.971 2.936 0.43
Total Liabilities 8.645 8.186 11.478 61.881 7.245
Total Long Term Debt 0 0 0 0 0
Long Term Debt 0 0 0 0
Other Liabilities, Total 0.127 0.3 0.527 0.77 0.382
Total Equity 38.625 46.072 79.22 58.119 10.098
Common Stock 0.019 0.018 0.018 0.008 0.01
Additional Paid-In Capital 623.652 622.906 620.611 581.823 199.019
Retained Earnings (Accumulated Deficit) -584.975 -576.76 -541.302 -523.603 -188.931
Total Liabilities & Shareholders’ Equity 47.27 54.258 90.698 120 17.343
Total Common Shares Outstanding 18.5975 17.8319 17.6883 8.16862 3.34052
Accounts Receivable - Trade, Net 2.41 2.815 3.457 3.422
Total Inventory 3.998 3.003 3.206 2.894
Goodwill, Net 21.053 21.623
Intangibles, Net 20.371 20.827 28.469 28.924
Other Current Liabilities, Total 1.858 0.964 1.125 0.986
Deferred Income Tax 0.367 0.555 0.615 0.615
Other Equity, Total -0.071 -0.092 -0.107 -0.109
Payable/Accrued 3.598 3.468 3.112
Preferred Stock - Non Redeemable, Net 0 0 0
Total Preferred Shares Outstanding 0.09539 0.09539 0.09539
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -61.933 -12.334 -23.676 -37.38 -34.765
Cash From Operating Activities -15.375 -10.409 -22.866 -29.432 -30.624
Cash From Operating Activities 0.232 0.34 0.479 0.581 0.33
Non-Cash Items 47.388 2.985 3.594 4.787 4.907
Cash Taxes Paid 0.102 0 0 0.007 0.002
Cash Interest Paid 0.296 0 0.719 0.642 0.562
Changes in Working Capital -2.741 -1.4 -3.263 2.58 -1.096
Cash From Investing Activities 1.855 -0.171 2.356 19.517 -21.856
Capital Expenditures -0.352 -0.171 -0.194 -1.282 -1.043
Other Investing Cash Flow Items, Total 2.207 0 2.55 20.799 -20.813
Cash From Financing Activities 33.299 0.43 13.378 9.994 0.613
Financing Cash Flow Items -3.234 0 -0.03 0
Issuance (Retirement) of Stock, Net 46.033 0 23.378 10.024 0.613
Issuance (Retirement) of Debt, Net -9.5 0.43 -10 0
Foreign Exchange Effects 0.029 0
Net Change in Cash 19.808 -10.15 -7.132 0.079 -51.867
Amortization 1.739
Deferred Taxes -0.06
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -8.215 -61.933 -26.475 -8.776 -4.874
Cash From Operating Activities -7.378 -15.375 -11.949 -4.149 -1.961
Cash From Operating Activities 0.094 0.232 0.132 0.04 0.007
Amortization 0.456 1.739 1.284 0.828 0.411
Deferred Taxes -0.187 -0.06 0
Non-Cash Items 0.831 47.388 16.165 2.454 2.61
Cash Taxes Paid 0 0.102 0.037 0.031 0.031
Changes in Working Capital -0.357 -2.741 -3.055 1.305 -0.115
Cash From Investing Activities 0.002 1.855 4.922 5.011 -0.119
Capital Expenditures -0.007 -0.352 -0.285 -0.196 -0.119
Other Investing Cash Flow Items, Total 0.009 2.207 5.207 5.207 0
Cash From Financing Activities 0 33.299 33.299 36.332 1
Issuance (Retirement) of Debt, Net 0 -9.5 -9.5 -9.5 1
Foreign Exchange Effects 0.021 0.029 0.014 0.012 0.019
Net Change in Cash -7.355 19.808 26.286 37.206 -1.061
Cash Interest Paid 0.296 0.296 0.296
Issuance (Retirement) of Stock, Net 46.033 46.033 45.832
Financing Cash Flow Items -3.234 -3.234

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

ReShape Lifesciences Inc. Company profile

About ReShape Lifesciences Inc

ReShape Lifesciences Inc., formerly Obalon Therapeutics, Inc., is a weight-loss solutions company. The Company is focused on offering an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band and associated program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest System is an investigational minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. The ReShapeCare Virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. The Company's Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kilograms/ square meter.

Financial summary

BRIEF: For the nine months ended 30 September 2021, ReShape Lifesciences Inc revenues increased from $1.5M to $10.5M. Net loss increased from $11M to $26.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $790K to $8.1M (expense), Selling, general and administrative - B increase of 62% to $10.9M (expense).

Industry: Advanced Medical Equipment & Technology (NEC)

1001 Calle Amanecer
SAN CLEMENTE
CALIFORNIA 92673
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

ETH/USD

3,556.84 Price
-0.610% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

BTC/USD

70,610.80 Price
-0.700% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.64 Price
-0.020% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading